CGEM Earnings Cullinan Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Net income
ROE
Reported EPS history
1–14 of 14
| Q3 2024 | 2024-09-30 | -2.30 | 2024-11-07 | 10-Q |
| Q2 2024 | 2024-06-30 | -1.61 | 2024-08-08 | 10-Q |
| Q1 2024 | 2024-03-31 | -0.86 | 2024-05-15 | 10-Q |
| FY 2023 | 2023-12-31 | -3.69 | 2024-03-14 | 10-K |
| Q3 2024 | 2023-09-30 | -3.15 | 2024-11-07 | 10-Q |
| Q2 2024 | 2023-06-30 | -2.24 | 2024-08-08 | 10-Q |
| Q1 2024 | 2023-03-31 | -1.42 | 2024-05-15 | 10-Q |
| FY 2023 | 2022-12-31 | 2.38 | 2024-03-14 | 10-K |
| Q3 2023 | 2022-09-30 | 2.96 | 2023-11-08 | 10-Q |
| Q2 2023 | 2022-06-30 | 3.51 | 2023-08-10 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.27 | 2023-05-11 | 10-Q |
| FY 2022 | 2021-12-31 | -1.52 | 2023-03-09 | 10-K |
| Q3 2022 | 2021-09-30 | -0.76 | 2022-11-14 | 10-Q |
| Q2 2022 | 2021-06-30 | -0.37 | 2022-08-10 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.